BMY-14802, also known as BMS-181100, is a drug with antipsychotic effects which acts as both a sigma receptor antagonist and a 5-HT1A receptor agonist.[1][2][3][4] It also has affinity for the 5-HT2 and D4 receptors.[5] The drug reached phase III clinical trials for the treatment of psychosis but was never marketed.[6]
Clinical data | |
---|---|
Other names | BMS-181100; MJ-14802 |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C18H22F2N4O |
Molar mass | 348.398 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |